Event Logo
Amgen, Novartis, Esteve and Merck, Sharpe & Dohme Ltd are just a few of the companies who will be coming together to share IP and patent protection best practice and work together to find the optimum way to prevent patent infringement of their companies’ crystalline forms.
From international IP perspectives at Novozymes to a scientist’s strategy for first time patent approval at Hovione, senior IP Counsel from across the globe will be presenting their areas of expertise, learning from one another and sharing tips at the 5th annual Developing IP Strategies for Crystalline Forms.
Discussion will centre on extensions of patent exclusivity, how applications to the EPO have changed over the last 12 months and what can be done to ensure first time approval. Delegates will also look at an international case law update for the EU, US and India, insight to judicial decisions in the UK and European Commission insight, reviewing the competition commissions report.
The conference is sponsored this year by leading IP law firm Fitzpatrick, Cella, Harper & Scinto and held on November 09-11, Regus Conference Centre, London.
For more information visit www.ipcrys.com
Photo:
http://www.prlog.org/
